BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 549 filers reported holding BIO-TECHNE CORP in Q1 2022. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $17,930 | -16.2% | 263,415 | +0.5% | 0.07% | -9.5% |
| Q2 2023 | $21,395 | -12.6% | 262,099 | -20.5% | 0.07% | -15.9% |
| Q1 2023 | $24,471 | -11.2% | 329,852 | -0.8% | 0.09% | -11.1% |
| Q4 2022 | $27,553 | -99.9% | 332,452 | +330.3% | 0.10% | +23.8% |
| Q3 2022 | $21,942,000 | -17.5% | 77,260 | +0.7% | 0.08% | -14.9% |
| Q2 2022 | $26,608,000 | -19.8% | 76,759 | +0.2% | 0.09% | +6.8% |
| Q1 2022 | $33,178,000 | -33.3% | 76,615 | -20.4% | 0.09% | -22.1% |
| Q4 2021 | $49,775,000 | +8.6% | 96,212 | +1.7% | 0.11% | +2.7% |
| Q3 2021 | $45,837,000 | +2.5% | 94,593 | -4.8% | 0.11% | +1.9% |
| Q2 2021 | $44,722,000 | +26.1% | 99,324 | +7.0% | 0.11% | +20.0% |
| Q1 2021 | $35,459,000 | +12.6% | 92,841 | -6.4% | 0.09% | +8.4% |
| Q4 2020 | $31,485,000 | +24.7% | 99,150 | -2.7% | 0.08% | +2.5% |
| Q3 2020 | $25,256,000 | -9.6% | 101,950 | -3.6% | 0.08% | -17.3% |
| Q2 2020 | $27,925,000 | +40.1% | 105,750 | +0.6% | 0.10% | +11.4% |
| Q1 2020 | $19,938,000 | -14.2% | 105,147 | -0.7% | 0.09% | +12.8% |
| Q4 2019 | $23,240,000 | -11.9% | 105,870 | -21.5% | 0.08% | -13.3% |
| Q3 2019 | $26,374,000 | +1042.7% | 134,788 | +1117.5% | 0.09% | +1025.0% |
| Q2 2019 | $2,308,000 | -96.6% | 11,071 | -96.7% | 0.01% | -95.8% |
| Q3 2018 | $68,632,000 | +21.5% | 336,248 | -12.0% | 0.19% | +15.2% |
| Q2 2018 | $56,500,000 | +16.4% | 381,884 | +18.8% | 0.16% | +14.6% |
| Q1 2018 | $48,541,000 | +17.3% | 321,376 | +0.6% | 0.14% | +22.0% |
| Q4 2017 | $41,381,000 | +4.7% | 319,422 | -2.3% | 0.12% | +2.6% |
| Q3 2017 | $39,514,000 | +2.8% | 326,863 | -0.1% | 0.12% | +0.9% |
| Q2 2017 | $38,455,000 | +75.4% | 327,274 | +51.8% | 0.11% | +72.7% |
| Q1 2017 | $21,920,000 | +50.8% | 215,645 | +52.6% | 0.07% | +50.0% |
| Q4 2016 | $14,534,000 | -44.3% | 141,336 | -40.7% | 0.04% | -45.0% |
| Q3 2016 | $26,105,000 | -25.8% | 238,398 | -23.6% | 0.08% | -27.3% |
| Q2 2016 | $35,169,000 | – | 311,866 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |